Our collective results, past and present, indicate that HUNK inhibition is effective in HER2+ breast cancer models [9, 10] and application of STU acts synergistically with the HER2 inhibitor lapatinib in JIMT-1 cells, a cell line inherently resistant to lapatinib. Here, ERBB2 is linked to breast carcinoma.